Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	151.58	76.98	70.93	36.7	63.42	66.9
Short-Term Investments	43.72	21.53	117.16	270.99	367.31	100.14
Cash & Cash Equivalents	195.3	98.5	188.09	307.69	430.73	167.03
Cash Growth	17.10%	-47.63%	-38.87%	-28.56%	157.87%	-18.95%
Receivables	0	0	0	6.48	0	0
Other Current Assets	3.83	4.27	2.5	2.98	3.71	8.84
Total Current Assets	199.13	102.77	190.6	317.15	434.44	175.87
Property, Plant & Equipment	65.53	67.03	113.86	119.06	47.1	45.85
Other Long-Term Assets	3.17	3.21	3.92	3.52	1.03	1.01
Total Long-Term Assets	68.7	70.24	117.78	122.58	48.13	46.86
Total Assets	267.83	173.01	308.37	439.73	482.57	222.73
Accounts Payable	1.9	1.92	2.24	1.39	2.81	4.1
Other Current Liabilities	19.65	22.99	30.01	19.93	18.06	15.31
Total Current Liabilities	21.55	24.91	32.25	21.32	20.87	19.41
Long-Term Debt	63.99	64.63	93.56	101.11	26.24	28.21
Other Long-Term Liabilities	0	0	1.05	1.11	1.11	0.15
Total Long-Term Liabilities	63.99	64.63	94.61	102.22	27.35	28.36
Total Liabilities	85.54	89.54	126.85	123.54	48.22	47.77
Total Debt	63.99	64.63	93.56	101.11	26.24	28.21
Debt Growth	-10.31%	-30.93%	-7.46%	285.39%	-7.01%	-
Retained Earnings	-944.56	-919.78	-802.61	-648.08	-502.54	-385.03
Comprehensive Income	-0.53	-0.47	-1.53	-0.71	-0.26	-0.73
Shareholders' Equity	182.29	83.47	181.52	316.19	434.35	174.96
Net Cash / Debt	131.31	33.88	94.53	206.58	404.49	138.82
Net Cash / Debt Growth	37.59%	-64.17%	-54.24%	-48.93%	191.38%	-32.64%
Net Cash Per Share	7.97	3.36	9.52	21.07	47.51	21.66
Working Capital	177.58	77.86	158.35	295.83	413.57	156.46
Book Value Per Share	11.06	8.28	18.29	32.25	51.01	27.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).